Avid Bioservices Inc (CDMO)

[Protector]

BioBS2012, the biomarker that PPHM PR'ed about is one that is scanned for in the blood. There is however a small 'appearance' latency that is probably due to Bavituximab's OWN latency. Let's say it needs to come up to speed.

As for the IO comparison, the Bavi+Doce did do better then Nivolumab data versus Docetaxel and on a LARGER footprint, in my opinion, we will see a same tail separation type (emphasising the bavituximab latency that we saw in previous clinical trials with chemo).

Pls note that all my info is second hand and that there may be errors in it. However I am quite confident myself about the info related to Sunrise (incl. biomarkers).